Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
Conditions
Brief summary
This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.
Detailed description
PRIMARY OBJECTIVES: I. To determine whether overall survival of patients with uterus-limited high-grade leiomyosarcoma is superior among patients assigned to treatment with adjuvant gemcitabine hydrochloride (gemcitabine) plus docetaxel followed by doxorubicin hydrochloride compared to patients assigned to observation. SECONDARY OBJECTIVES: I. To determine whether treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin improves recurrence-free survival of patients with uterus-limited high-grade leiomyosarcoma compared to observation. II. To explore the impact of potential predictors of recurrence or death such as patient age, institution reported tumor size, cervix involvement (yes or no), and mitotic rate. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo computed tomography (CT) and/or magnetic resonance imaging (MRI). Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3. Arm II: Patients undergo clinical observation. After completion of study treatment, patients in both arms are followed up every 4 months for 3 years and then every 6 months for 2 years.
Interventions
OTHERClinical Observation
Patients followed clinically
DRUGDocetaxel
Given IV
DRUGDoxorubicin Hydrochloride
Given IV
BIOLOGICALFilgrastim
Given subcutaneously (SC)
DRUGGemcitabine Hydrochloride
Given IV
BIOLOGICALPegfilgrastim
Given SC
Sponsors
National Cancer Institute (NCI)
Gynecologic Oncology Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with high-risk uterine leiomyosarcoma (LMS), Federation of Gynecology and Obstetrics (FIGO) stage I (confined to corpus +/- cervix); patients with known uterine serosa involvement are not eligible; patients should have had, at least, a complete hysterectomy (including removal of the cervix); bilateral salpingo-oophorectomy is not required * Institutional pathology review calls the uterine leiomyosarcoma ?high grade? * Additionally, if the pathology report indicates a mitotic rate, the mitotic rate should be greater than or equal to 5 mitoses/10 high-power field * All patients must be no longer than 12 weeks (3 months) from surgical resection of cancer at the time of enrollment on study; if a patient requires a second operation to complete her surgery, i.e., trachelectomy to remove the cervix and/or bilateral salpingo-oophorectomy (BSO), the 12 weeks may be counted from the time of the second operation * Patients who had a ?morcellation? hysterectomy procedure that involved morcellation within the peritoneal cavity are eligible IF a second operation is performed and biopsies from the second procedure show no evidence of leiomyosarcoma * All patients must have no evidence of persistent or metastatic disease as documented by a post-resection computed tomography (CT) of the chest/abdomen/pelvis or by CT chest + magnetic resonance imaging (MRI) abdomen/pelvis; the post-resection imaging studies should be performed within 4 weeks of registration on study * Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL (ANC \>= 1.5 x 10\^9/liter \[L\]) * Platelets greater than or equal to 100,000/mcL (platelets \>= 100 x 10\^9/L) * Hemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L) * Creatinine less than or equal to 1.5 x institutional upper limit of normal (ULN) * Bilirubin\* within normal range * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\])\* and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\])\* less than or equal to 2.5 times ULN * Alkaline phosphatase\* less than or equal to 2.5 x ULN * \* Patients with a history of Gilbert?s syndrome may be eligible provided total bilirubin is less than or equal to 1.5 x ULN and the AST, ALT, and alkaline phosphatase meet the criteria detailed * Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 * Patients with Gynecologic Oncology Group (GOG) performance status of 0 or 1 OR Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 OR Karnofsky performance status (PS) \>= 80% * Patients who have met the pre-entry requirements specified * Patients must have signed an approved informed consent * Patients participating through United States (U.S.) sites must sign an approved and authorization permitting release of personal health information * Patients should be free of active infection requiring antibiotics (with the exception of an uncomplicated urinary tract infection \[UTI\])
Exclusion criteria
* Patients who have had prior therapy with docetaxel, gemcitabine hydrochloride, or doxorubicin hydrochloride at any time in their history * Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are ineligible if there is any evidence of other malignancy being present within the last five years; patients are also ineligible if their previous cancer treatment contraindicates this protocol therapy * Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80 * Patients with GOG performance status of 2, 3 or 4; or ECOG performance status of 2, 3 or 4 * Patients who are breast-feeding * Patients with a known history of congestive heart failure or cardiac ejection fraction \< 50% (or less than institutional normal limits); echocardiogram (ECHO) or multigated acquisition scan (MUGA) is not required prior to enrollment; for patients assigned to the chemotherapy arm, an ECHO or MUGA should be done within 6 months of day 1 of gemcitabine-docetaxel treatment * Patients who enroll on study and are randomized to Regimen I (chemotherapy ) and then are found on baseline ECHO or MUGA to have cardiac ejection fraction \< 50% or below institutional normal will remain ON study; such patients will receive gemcitabine + docetaxel for 4 cycles but will NOT receive any doxorubicin treatment; they will continue treatment follow-up as outlined for all patients assigned to Regimen I * Patients with a history of prior whole pelvic radiation * Concurrent treatment with hormone replacement therapy is permitted at the discretion of the treating physician; patients who have been taking hormonal/hormone blocking agents for breast cancer or breast cancer prevention or other indication are eligible; use of anti-hormonal agents (tamoxifen, medroxyprogesterone, aromatase inhibitors) is permitted at the discretion of the treating physician; documentation of concurrent medications is required * Patients with recurrent uterine LMS * Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible * Patients with gross residual or metastatic tumor findings following complete surgical treatment for uterine LMS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Experienced Death | Follow-up every 4 months for 3 years, then every 6 months for 2 years. | The duration of time from study entry to time of death or the date of last contact. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Approximately 4 years | — |
| Number of Participants With Recurrence | Follow-up every 4 months for 3 years, then every 6 months for 2 years. | The duration of time from study entry to time of recurrence or death, whichever occurred first, or the date of last contact. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Univariate and Multi-variable Prognostic Significance of Baseline Clinical, Pathologic, or Demographic Factors | Up to 5 years | Analyses will be carried out using proportional hazards models of both survival and recurrence. |
Countries
Belgium, France, Netherlands, Norway, Spain, United Kingdom, United States, Venezuela
Participant flow
Recruitment details
This study accrued 38 patients from June 2012 to September, 2016. Study was closed due to accrual futility.
Participants by arm
| Arm | Count |
|---|---|
| Regimen 1 Gemcitabine 900 mg/m2 IV days 1 and 8 Docetaxel 75 mg/m2 IV day 8 GCSF 5 micrograms/kg days 9-15 or pegfilgrastim 6 mg day 9 or 10 Every 21 days for 4 cycles CT/MRI imaging to confirm disease-free Doxorubicin 60 mg/m2 IV every 21 days for 4 cycles | 20 |
| Regimen II Observation | 18 |
| Total | 38 |
Baseline characteristics
| Characteristic | Regimen 1 | Total | Regimen II |
|---|---|---|---|
| Age, Customized 20-29 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 30-39 years | 2 Participants | 2 Participants | 0 Participants |
| Age, Customized 40-49 years | 4 Participants | 8 Participants | 4 Participants |
| Age, Customized 50-59 years | 10 Participants | 17 Participants | 7 Participants |
| Age, Customized 60-69 years | 3 Participants | 8 Participants | 5 Participants |
| Age, Customized 70-79 years | 1 Participants | 3 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 16 Participants | 33 Participants | 17 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 6 Participants | 2 Participants |
| Race (NIH/OMB) White | 15 Participants | 26 Participants | 11 Participants |
| Sex: Female, Male Female | 20 Participants | 38 Participants | 18 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 5 / 20 | 1 / 18 |
| other Total, other adverse events | 16 / 20 | 12 / 18 |
| serious Total, serious adverse events | 5 / 20 | 0 / 18 |
Outcome results
Primary
Number of Participants Who Experienced Death
The duration of time from study entry to time of death or the date of last contact.
Time frame: Follow-up every 4 months for 3 years, then every 6 months for 2 years.
Population: Eligible and evaluable participants
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen 1 | Number of Participants Who Experienced Death | 5 Participants |
| Regimen II | Number of Participants Who Experienced Death | 1 Participants |
Secondary
Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
Time frame: Approximately 4 years
Population: eligible and randomized patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen 1 | Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | 10 participants |
| Regimen II | Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | 1 participants |
Secondary
Number of Participants With Recurrence
The duration of time from study entry to time of recurrence or death, whichever occurred first, or the date of last contact.
Time frame: Follow-up every 4 months for 3 years, then every 6 months for 2 years.
Population: Eligible and evaluable participants
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen 1 | Number of Participants With Recurrence | 8 participants |
| Regimen II | Number of Participants With Recurrence | 8 participants |
Other Pre-specified
Univariate and Multi-variable Prognostic Significance of Baseline Clinical, Pathologic, or Demographic Factors
Analyses will be carried out using proportional hazards models of both survival and recurrence.
Time frame: Up to 5 years